The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 15 Feb 2017Publisher:Xia & He PublishingJournal:Journal of Exploratory Research in Pharmacology, volume 1, pages 1-6 (eissn: 2572-5505,

Copyright policy )

Authors: Devika Kapuria; Rajiv Chhabra;

doi: 10.14218/jerp.2016.00016

The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease

- Summary
- Metrics

Abstract

The advent of targeted biologic therapies for debilitating disorders such as Crohn’s disease (CD) and Ulcerative Colitis (UC) has changed management and significantly improved outcomes. However, biologic agents are expensive, and the introduction of biosimilar medications for the treatment of inflammatory bowel diseases presents a lower-cost alternative. In this review, the mechanism of action, pharmacokinetics, efficacy and adverse effects associated with biosimilar CT-P13 in the treatment of inflammatory bowel disease are discussed.

Related Organizations

University of Missouri
United States

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average